EP. 3: Monitoring, Dosing, and Rechallenge Strategies With Datopotamab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
Key Points
-
Imaging frequency with datopotamab deruxtecan (Dato-DXd) is individualized in practice, typically every 8 to 12 weeks, with closer monitoring for symptomatic or high-risk patients.
-
The standard Dato-DXd dose is 6 mg/kg given intravenously every 3 weeks, with defined dose reductions and structured infusion monitoring.
-
Temporary treatment holds and rechallenges after low-grade toxicities are feasible and generally do not result in loss of clinical benefit.
During this Clinical Insights discussion, Rahul Gosain, MD, MBA, of Wilmot Cancer Institute, and Rohit Gosain, MD, of Roswell Park Comprehensive Cancer Center, were joined by Blanca A. Ledezma, NP, of UCLA Health; Aaron Lisberg, MD, of UCLA Health; and Sarah B. Sunshine, MD, of the University of Maryland School of Medicine, to discuss monitoring, dosing, and toxicity management with Dato-DXd following its recent approval.
Imaging Frequency and Clinical Monitoring
In clinical trials evaluating Dato-DXd, imaging was performed as often as every 6 weeks, largely driven by protocol requirements and close surveillance for interstitial lung disease (ILD). Ms. Ledezma explained that in routine practice, imaging intervals are individualized based on patient stability and symptoms. For clinically well patients who respond to therapy, scans are typically obtained every 8 to 12 weeks.
When there is concern for pulmonary toxicity, such as new or worsening respiratory symptoms or prior imaging abnormalities suggesting pneumonitis, imaging frequency is increased to every 6 to 8 weeks, or sooner if clinically indicated. Patients with suspected or confirmed ILD are monitored closely with frequent clinic visits, phone calls, or virtual check-ins while receiving corticosteroids.
Dosing, Premedication, and Rechallenge Considerations
Ms. Ledezma reviewed the standard administration of Dato-DXd, which is given at a dose of 6 mg/kg intravenously every 3 weeks. If dose reduction is required due to toxicity, the first reduction is to 4 mg/kg, followed by 3 mg/kg. Patients who do not tolerate the second dose reduction should discontinue treatment permanently.
The first infusion is administered over 90 minutes, with subsequent infusions shortened to 30 minutes if tolerated. Patients are observed for 1 hour after the first 2 cycles and for 30 minutes during later cycles. Premedication, including antihistamines and antipyretics to prevent infusion reactions, as well as aggressive antiemetic prophylaxis, is an important component of care. Because Dato-DXd is classified as highly emetogenic, regimens may include a 5-HT3 antagonist, dexamethasone, a neurokinin-1 receptor antagonist, and olanzapine, depending on institutional guidelines.
The discussion reinforced that temporary treatment holds for low-grade toxicities—particularly ILD—do not appear to compromise efficacy.